Nanogen Closes Acquisition of Epoch Biosciences
Nanogen last week closed its acquisition of Epoch Biosciences for $97 million. The deal was originally announced in September, and was approved by shareholders on Dec. 15.
Epoch ceased trading on the Nasdaq exchange at market close last Thursday.
Nanogen shareholders approved the issuance of shares of common stock for the deal, and also approved an amendment to the company’s certificate of incorporation increasing the number of authorized shares of Nanogen common stock to 135 million.